International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 10 Issue 5, Sep-Oct 2026 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

Synergistic Effect to Treat Antimicrobial Resistance (AMR) with Antibiotics and Nanoparticles

Ms. Bandula Anjali[1], Ms. Mohammed Sheenamini[2]*, Mr. Rakesh Chandra Parida[3]

[1]PG Scholar, School of Pharmaceutical Sciences and Technologies,
[2]Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences and Technologies,
[1,2]Jawaharlal Nehru Technological University Kakinada, Andhra Pradesh, India
[3]Research Scholar, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Chennai, Tamil Nadu, India
*Corresponding Author: Ms. Mohammed Sheenamini

ABSTRACT

Antimicrobial resistance (AMR) represents one of the most critical global health challenges of the modern era [10]. The progressive loss of antibiotic efficacy has complicated infection control and increased morbidity, mortality, and healthcare costs [1]. To counteract this, innovative combination strategies employing antibiotics together with metallic nanoparticles (MNPs) or plant-derived bioactive compounds have emerged as promising approaches [10]. MNPs offer several advantages, including broad-spectrum antimicrobial activity, physicochemical stability, and the potential to minimize the development of resistance [7]. Their integration with conventional antibiotics often leads to synergistic effects, wherein combined agents produce a therapeutic response greater than the sum of their individual actions [8]. Such synergy enables enhanced bacterial eradication at reduced antibiotic doses [1]. Experimental evidence demonstrates that biologically synthesized silver nanoparticles (Bio-AgNPs) used with ampicillin (AMP) or enrofloxacin (ENRO) markedly improved antibacterial performance and suppressed resistance in multidrug-resistant (MDR) strains, underscoring a viable pathway for clinical translation [1]. The ultimate goal of this approach is to restore the effectiveness of traditional antibiotics that have lost potency due to emerging resistance [1].

How to cite this paper: Ms. Bandula Anjali | Ms. Mohammed Sheenamini | Mr. Rakesh Chandra Parida "Synergistic Effect to Treat Antimicrobial Resistance (AMR) with Antibiotics and Nanoparticles" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-10 | Issue-5, October 2026, pp.317-322, URL: www.ijtsrd.com/papers/ijtsrd142116.pdf


IJTSRD142116

Copyright © 2026 by author (s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

1. INTRODUCTION

1.1. The Escalating Crisis of Antimicrobial Resistance (AMR)

The mechanism of antimicrobial resistance and nanoparticle interaction is illustrated in Fig. 1.




Overview of antimicrobial resistance mechanisms in pathogenic microorganisms, including enzymatic degradation, target modification, reduced permeability, and efflux pump-mediated resistance.

Antimicrobial resistance (AMR) has emerged as one of the greatest threats to public health, representing a major clinical and economic burden worldwide. The continuous rise of resistant bacterial strains has eroded the efficacy of many conventional antibiotics, making once-manageable infections increasingly difficult to treat [1]. The World Health Organization (WHO) recognizes AMR as a top-tier global health priority, warning that without immediate intervention, routine surgical procedures and minor infections could again become fatal.

Epidemiological data highlight the alarming magnitude of the problem: approximately 1.27 million deaths were directly attributed to bacterial AMR in 2019, while an additional 4.95 million deaths were associated with infections involving resistant pathogens [3][1]. The situation is further exacerbated by the misuse and overuse of antibiotics in clinical, veterinary, and agricultural settings, which accelerate the selection and spread of resistant strains.

The underlying cause of AMR lies in the remarkable genetic adaptability and biochemical versatility of microorganisms. Bacteria can survive antimicrobial exposure through several defensive mechanisms, including enzymatic degradation of drugs (e.g., β-lactamase production), modification of target sites (e.g., altered penicillin-binding proteins), inhibition of drug uptake, and active efflux of antibiotics via membrane transporters [6].

The synergistic antibacterial activity of antibiotics with nanoparticles is shown in Fig. 2.



Schematic representation of the synergistic interaction between antibiotics and nanoparticles for enhanced antimicrobial activity against resistant pathogens

Horizontal gene transfer—via conjugation, transformation, or transduction—facilitates the rapid dissemination of resistance determinants across bacterial species and genera [10]. Collectively, these strategies allow bacteria to persist and proliferate despite therapeutic intervention, rendering many antibiotics increasingly ineffective.

Table 1. Presents the classification of commonly used antibiotics, their target organisms, and the major mechanisms responsible for antimicrobial resistance.

Antibiotic	Class	Target Organisam	Limitation(Resistance)
Ampicillin	β-Lactam	Gram +ve /-ve	β-Lactamase degradation
Enrofloxacin	Fluoroquinolone	Gram -ve	DNAgyrase mutation
Tetracycline	Broad-spectrum	Many bacteria	Efflux pump

1.2. Combination Therapy: Integrating Antibiotics with Nanoparticles or Phytochemicals

Given the multifactorial nature of AMR, single-drug therapies are often insufficient to eradicate resistant pathogens. Consequently, combination therapy—the strategic use of multiple antimicrobial agents with complementary mechanisms of action—has become an essential approach to overcoming resistance. Two major combinatorial platforms have gained attention in recent years: antibiotic–phytochemical and antibiotic–nanoparticle systems [2].

Phytochemical-basedcombinations.

Plants have long served as rich reservoirs of bioactive secondary metabolites with antimicrobial, antioxidant, and


anti-inflammatory properties. Polyphenols, flavonoids, alkaloids, and terpenoids derived from medicinal plants exhibit the ability to disrupt bacterial membranes, inhibit efflux pumps, or interfere with quorum sensing and biofilm formation [2]. When used alongside antibiotics, these phytochemicals can restore or enhance drug susceptibility through synergistic interactions. However, if either component (extract or antibiotic) shows negligible inhibition on its own, true synergy typically requires higher concentrations or optimized ratios, emphasizing the need for detailed pharmacodynamic evaluation.

Nanoparticle-basedcombinations.

Metallic nanoparticles (MNPs)—including silver (AgNPs), gold (AuNPs), copper oxide (CuO NPs), and zinc oxide (ZnO NPs)—exhibit potent antimicrobial activities and physicochemical versatility. Their nanoscale dimensions endow them with a large surface-area-to-volume ratio, tunable surface charge, enhanced solubility, and high functional flexibility, all of which improve bacterial interaction and cellular penetration [7][9]. MNPs demonstrate inherent bactericidal activity, improved thermal and chemical stability, and, notably, a reduced tendency for resistance development. When used in conjunction with antibiotics, these materials can potentiate antimicrobial action through multi-site interference, providing a robust and adaptable therapeutic framework against multidrug-resistant (MDR) pathogens.

1.3. Concept of Synergistic Interaction


The figure highlights the potential of nanoparticle-antibiotic combinations as an effective strategy to overcome antimicrobial resistance (AMR).in Fig. 3.



Classification of nanoparticles used in antimicrobial therapy, including metallic, metal oxide, polymeric, and lipid-based nanoparticles.

The concept of **synergy** in antimicrobial pharmacology refers to a situation in which the combined efficacy of two agents exceeds the sum of their individual effects [3]. In the context of AMR management, synergy is particularly desirable because it allows for dose reduction, decreased toxicity, and delayed emergence of resistance.

The represents the global burden and projected rise of Antimicrobial Resistance (AMR) deaths worldwide in Fig. 4.



Proposed mechanisms of antibacterial action of nanoparticles, including membrane disruption, reactive oxygen species generation, biofilm inhibition, and intracellular target interference.

In combinatorial systems involving nanoparticles and antibiotics, the interaction is primarily biological rather than chemical, meaning that the molecules themselves are not modified but their combined biological actions complement each other. For instance, nanoparticles can enhance antibiotic uptake by increasing membrane permeability, disrupt bacterial homeostasis, or create microenvironments that facilitate intracellular drug diffusion [1].

Silver nanoparticles (AgNPs) have been extensively investigated as model systems due to their robust antibacterial potential. Although the precise mechanism remains multifaceted, four principal processes have been proposed:

1. **Surface adhesion and membrane alteration** – AgNPs attach to bacterial cell walls, increasing permeability and compromising integrity.
2. **Intracellular penetration and biomolecular interaction** – NPs enter the cytoplasm, binding to proteins and nucleic acids, leading to metabolic disruption.
3. **Ion release-mediated toxicity** – The liberation of Ag^{+} ions interferes with enzymatic pathways and respiratory processes.
4. **Reactive oxygen species (ROS) generation** – Oxidative stress damages cellular components and alters gene expression [1][7][9].

Through these parallel mechanisms, AgNPs act as multifunctional antimicrobial enhancers, capable of amplifying the bactericidal effect of antibiotics while simultaneously hindering the evolution of new resistance traits.

1.4. Rationale for Combination Therapy in Overcoming AMR

The integration of nanoparticles with antibiotics offers a multi-level attack strategy capable of bypassing bacterial defence networks [7][8]. Since MNPs target several cellular structures and biochemical pathways simultaneously, bacteria would require multiple concurrent genetic adaptations within a single cell to develop resistance—an event considered statistically improbable [4]. This unique characteristic makes the combination approach especially valuable for addressing persistent and MDR infections.

Furthermore, MNPs can restore the therapeutic potential of antibiotics that have lost effectiveness by increasing drug uptake, destabilizing resistance enzymes, and disrupting biofilm matrices that shield bacteria from antimicrobial penetration [6]. The resulting synergistic activity not only enhances bacterial eradication but also reduces the necessary antibiotic dose, minimizing toxicity and ecological impact.

Hence, the antibiotic–nanoparticle paradigm represents a scientifically justified and practically feasible route toward next-generation antimicrobial therapies. It leverages the physicochemical properties of nanomaterials and the pharmacological specificity of antibiotics to deliver superior, broad-spectrum, and resistance-resilient treatments [1][8].

Discussion:

The combination of silver nanoparticles (AgNPs) with conventional antibiotics offers a promising approach to counteract antimicrobial resistance (AMR). AgNPs possess broad-spectrum antibacterial activity that depends mainly on their size, surface charge, and concentration, which influence their interaction with microbial membranes and intracellular targets.

When used together, AgNPs and antibiotics exhibit synergistic effects, where the overall antimicrobial activity exceeds the sum of their individual actions. This synergy is primarily due to AgNPs enhancing antibiotic uptake, disrupting bacterial membranes, and inducing oxidative stress, which collectively weaken bacterial defence mechanisms [1][3][7].

Table 2. summarizes the synergistic antibacterial effects of antibiotics combined with nanoparticles against resistant bacterial pathogens.

Antibiotic	Nanoparticle	Target bacteria	outcome
Ampicillin	AgNps	Escherichia coli	Increased inhibition of growth
Enrofloxacin	AgNps	Salmonella typhimurium	Reduced resistance and biofilm formation

Selected studies reporting synergistic effects of antibiotics and nanoparticles against antimicrobial-resistant microorganisms.

Mechanistically, AgNPs adhere to the cell surface, increase membrane permeability, and release Ag^+ ions that interact with DNA and key metabolic enzymes, leading to loss of function and cell death. The generation of reactive oxygen species (ROS) further damages cellular components. These processes create an intracellular environment that facilitates the entry and activity of antibiotics, especially those targeting protein synthesis and cell wall formation [4][6].


Importantly, AgNPs can also reduce the emergence of bacterial resistance by targeting multiple pathways simultaneously. Since resistance mutations usually affect specific targets, the multisite action of AgNPs makes adaptation more difficult. Additionally, silver ions can interfere with plasmid replication and conjugation, thereby limiting the horizontal transfer of resistance genes [8].

From a pharmaceutical perspective, AgNP–antibiotic systems improve drug stability, solubility, and bioavailability, while allowing potential dose reduction and decreased toxicity. The green synthesis of AgNPs using plant-based reducing agents further enhances safety and biocompatibility, creating a sustainable platform for antimicrobial formulation development [2][9].

Overall, this synergistic approach not only strengthens antibacterial efficacy but also offers a viable strategy to extend the therapeutic lifespan of existing antibiotics and control the spread of multidrug-resistant infections [1][7][10].

Future Directions

The green synthesis process of silver nanoparticles (AgNPs) using plant leaf extracts in Fig. 5.



Future prospects and challenges of nanoparticle-antibiotic combination therapy for combating antimicrobial resistance.

Future research on nanoparticle–antibiotic combinations should focus on mechanistic clarity, formulation optimization, and clinical translation. Although the synergistic benefits of metallic nanoparticles (especially AgNPs) are well documented, the precise molecular interactions that enhance antibiotic performance are not fully understood [5][7]. Advanced studies using omics-based tools (proteomics, transcriptomics) and molecular imaging can help identify specific targets affected by AgNPs during bacterial inhibition.

From a formulation perspective, efforts should aim to optimize nanoparticle size, surface charge, coating materials, and controlled-release systems to improve selective delivery, minimize cytotoxicity, and maintain antimicrobial potency [4][8]. Furthermore, the use of green synthesis routes—employing biological or plant-based reducing agents—should be prioritized to ensure environmental sustainability and biocompatibility [9].

Before clinical adoption, detailed toxicological and pharmacokinetic studies are crucial. Evaluating nanoparticle accumulation, systemic exposure, and long-term safety will determine their feasibility for both systemic and topical use. Regulatory frameworks must also evolve to assess these hybrid nano-antimicrobial systems effectively [6][10].

Conclusion:

The escalating crisis of antimicrobial resistance necessitates multifaceted, innovative solutions. Combining metallic nanoparticles with conventional antibiotics provides a potent, synergistic strategy capable of restoring the efficacy of drugs compromised by resistance mechanisms. This approach functions by enhancing drug permeability, disrupting bacterial defences, and targeting multiple molecular pathways, thereby minimizing the likelihood of resistance development [1][5][7].

Biogenic and green-synthesized AgNPs, in particular, hold immense promise due to their broad-spectrum activity, tunable physicochemical properties, and sustainable production routes. Their integration with existing antibiotics not only revives the potency of conventional therapies but also enables dose reduction and lower toxicity, which are crucial for clinical applications [2][8][9].

In summary, nanoparticle–antibiotic hybrid systems represent a transformative approach in antimicrobial therapy. By merging nanotechnology with pharmacology, this platform offers a flexible, adaptive, and highly effective means to combat multidrug-resistant pathogens and potentially redefine the future of infectious disease treatment [1][4][10].

Funding Declaration:
No funding was received for this research.

Ethics Declaration:
Not Applicable

References:

[1] Santos, M. H. d. M., et al. (2025). Silver Nanoparticle-Antibiotic Combinations: A Strategy to Overcome Bacterial Resistance in *Escherichia coli*, *Salmonella Enteritidis* and *Staphylococcus aureus*. *Antibiotics*, 14(10), 960

[2] Gideon, M., & Ladan, Z. (2023). Synergistic Combinatorial Strategy for Combating Antimicrobial Resistance (AMR) in Clinical Bacteria by Combining Antibiotics with Plant Extracts. *Fine Chemical Engineering*, 4(1), 1-12.

[3] Aabed, K., & Mohammed, A.E. (2021). Synergistic and Antagonistic Effects of Biogenic Silver Nanoparticles in Combination With Antibiotics Against Some Pathogenic Microbes. *Frontiers in Bioengineering and Biotechnology*, 9, 652362

[4] Mondal, S. K., et al. (2024). Antimicrobial nanoparticles: current landscape and future challenges. *RSC Pharmaceutics*, 1(3), 388-402

[5] Casals, E., et al. (2025). Silver Nanoparticles and Antibiotics: A Promising Synergistic Approach to Multidrug-Resistant Infections. *Microorganisms*, 13(4), 952.

[6] Ngoepe, M.P., Schoeman, S., & Roux, S. (2025). Challenges Associated with the Use of Metal and Metal Oxide Nanoparticles as Antimicrobial Agents: A Review of Resistance Mechanisms and Environmental Implications. *Biotechnology Journal*, 20, e70066

[7] Liao, Y., et al. (2025). Antimicrobial Mechanisms of Metal-Based Nanomaterials. *International Journal of Nanomedicine*, 20, 12879-12887.

[8] Abdullah, et al. (2024). Recent Advances in the Development of Metal/Metal Oxide Nanoparticle and Antibiotic Conjugates (MNP-Antibiotics) to Address Antibiotic Resistance: Review and Perspective. *Int. J. Mol. Sci.*, 25(16), 8915

[9] Pammi, S.V.N., et al. (2025). Unlocking the synergistic potential of green metallic nanoparticles and antibiotics for antibacterial and wound healing activities. *iScience*, 28(6), 11251

[10] Khairnar, S.V., et al. (2025). Strategies to overcome antibiotic resistance: silver nanoparticles and vancomycin in pathogen eradication. *RSC Pharmaceutics*, 2(3), 455-479.